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Salmonella enterica serotype Choleraesuis is a highly
invasive pathogen that infects humans and causes sys-
temic infections that require antimicrobial therapy.
Surveillance in Taiwan showed that fluoroquinolone resist-
ance in S. Choleraesuis markedly increased from 2000 to
2003, reaching approximately 70% in 2003. 
O
f the more than 2,000 nontyphoid Salmonella
serotypes, Salmonella enterica serotype Choleraesuis
is extremely invasive and usually associated with bac-
teremia in humans. Before 1999, this serotype was suscep-
tible to fluoroquinolones (1). Since 2000, we have
recorded rapidly increasing resistance to ciprofloxacin in
S. Choleraesuis isolated from both human and swine
sources in Taiwan (2). This finding is a cause for concern
because fluoroquinolones are first-line drugs to treat sys-
temic, nontyphoid salmonellosis. We conducted a prospec-
tive, laboratory-based surveillance study of fluoro-
quinolone resistance in S. Choleraesuis isolated from
humans in four major teaching hospitals across Taiwan
from 2000 to 2003.
The Study
Chang Gung Memorial Hospital in Keelung is a 1,000-
bed hospital. Chang Gung Memorial Hospital in Taoyuan,
which includes Chang Gung Children’s Hospital, is locat-
ed in Taoyuan and has a capacity of 4,000 (which includes
an additional 500 beds for Chang Gung Children’s
Hospital). Chang Gung Memorial Hospital in Kaohsiung,
in southern metropolitan Taiwan, is a 2,000-bed hospital.
Chang Gung Memorial Hospital in Chiayi, which was
open for service in December 2001, is an 800-bed hospital.
All four are teaching hospitals affiliated with Chang Gung
University in Taoyuan, Taiwan. The geographic locations
of these hospitals are shown in Figure 1. All S.
Choleraesuis isolates were cultured and identified accord-
ing to standard methods (3) in the clinical microbiologic
laboratories of the four hospitals. No major changes were
made in the policy concerning identification of Salmonella
during the study years. Salmonella isolates were first
checked with O antisera (Becton Dickinson and Co.,
Franklin Lakes, NJ) for their serogroups by the slide
agglutination method. Because it causes invasive infec-
tions, S. Choleraesuis was specifically identified if a nega-
tive result was found in the citrate utilization test for any
isolate identified as serogroup C1 Salmonella. H antiserum
has been used to verify the accuracy of this procedure in
our previous studies (1,2). The susceptibility to
ciprofloxacin of the isolates was investigated by a standard
disk-diffusion method (4). Susceptible or resistant isolates
were defined according to the criteria suggested by the
National Committee for Clinical Laboratory Standards (4);
isolates in the intermediate category were deemed as
resistant in this study.
The annual isolate number of S. Choleraesuis among
the four Chang Gung Memorial Hospitals and the resist-
ance to ciprofloxacin from 2000 to 2003 are summarized
in Figure 2. An apparent growing trend of resistance was
observed. The overall resistance rate of the isolates collect-
ed from the four hospitals increased from 32.3% in 2000 to
56.5% in 2001, 61.8% in 2002, and 71.8% in 2003 (p <
0.00001 by chi-square test). Ciprofloxacin resistance rate
was generally lower in 2000; however, such resistance
increased to >50% in Keelung, Taoyuan, and the newly
opened Chiayi Chang Gung Memorial Hospitals in 2001 to
2002. The resistance rate remained constantly high in
2003. The highest rate was found in clinical isolates from
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Figure 1. Geographic position of the four hospitals in Taiwan where
Salmonella enterica Choleraesuis isolates were collected and sur-
veyed for their susceptibility to ciprofloxacin, 2000–2003.Chang Gung Memorial Hospital in Chiayi: 11 (85%) of 13
isolates were resistant in 2002. Although approximately
30% of the S. Choleraesuis isolates were resistant to
ciprofloxacin in Chang Gung Memorial Hospital,
Kaohsiung, before 2002, an upsurge to 76% was detected
in this hospital in 2003. 
Conclusions
S. Choleraesuis is an infrequent serotype of Salmonella
and has been isolated from humans in the United States
(5). The annual reported number of S. Choleraesuis iso-
lates from humans was approximately 80 from 1990 to
1996. The number decreased gradually thereafter, with an
annual isolate number of 49 in 1997, 36 in 1998, 34 in
1999, and 15 in 2000 (5).
However, this highly invasive serotype is of particular
concern in Taiwan; it was the second most common
Salmonella isolate found in humans in two independent
epidemiologic surveys (6,7). The reason for the difference
between Taiwan and United States is an issue of interest. S.
Choleraesuis is highly host-adapted to pigs. We have found
that S. Choleraesuis isolates from humans and swine had
the same or similar DNA fingerprints, which suggests that
human infections were derived from pigs (2). Such infec-
tion likely arose as a result of the contamination of a food
or water source. Eating pig offal by the local population
likely contributed to the high prevalence of S. Choleraesuis
infection in some areas of Taiwan. 
Results of this surveillance study reflect the current sta-
tus of fluoroquinolone resistance in S.  Choleraesuis in
Taiwan. The four hospitals surveyed in this study are locat-
ed in different regions across Taiwan, the surveillance is
prospective and longitudinal in design, and the overall iso-
late number examined is large enough to draw a conclu-
sion. Minor geographic variation in the rate of
ciprofloxacin resistance was observed. Among the four
hospitals surveyed, Chang Gung Memorial Hospital in
Kaohsiung is the only one located in a metropolitan area.
Sanitation in a metropolitan area is better than that in the
rural or country areas. The spread of resistant clones,
therefore, may be slower in this area, as reflected by the
lower number of S. Choleraesuis infections treated in
Kaohsiung Chang Gung Memorial Hospital compared to
those treated in Linko Chang Gung Memorial Hospital.
Moreover, most pig farms are not located in large cities.
These factors might explain why the spread of resistance in
Kaohsiung was slower than in other regions before 2002.
In contrast, isolates from Chiayi Chang Gung Memorial
Hospital, which is located in the underdeveloped, south-
western coastal region of Taiwan, showed the highest rate
of resistance to ciprofloxacin in 2002. The up-to-date data
obtained in 2003 confirmed a wide dissemination of
ciprofloxacin-resistant S. Choleraesuis across Taiwan. 
We have found that all of the resistant strains carried
mutations that give rise to the substitution of phenylalanine
for serine at position 83 and asparagine for aspartic acid at
position 87 in GyrA (2). In addition, mutations leading to
an amino acid change from serine to isoleucine at position
80 in ParC were demonstrated in the ciprofloxacin-resist-
ant S. Choleraesuis isolates (8,9). The emergence of fluo-
roquinolone resistance in S. Choleraesuis was mainly due
to the dissemination of an endemic, resistant clone (2,9).
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Figure 2. The annual isolate num-
ber (in bars) and the rate of
ciprofloxacin resistance (in lines)
among the isolates from the four
hospitals in which Salmonella
enterica Choleraesuis isolates
were collected and surveyed for
their susceptibility to ciprofloxacin,
2000–2003. The emergence of fluoroquinolone resistance in this
highly invasive nontyphoid Salmonella serotype repre-
sents a serious threat to public health and clinical medi-
cine. Most of the ciprofloxacin-resistant S. Choleraesuis
were also multidrug resistant to the conventional antimi-
crobial agents (1,2,6,10). This resistance indicates that
extended-spectrum cephalosporins become the only reli-
able agent in the treatment of systemic infections caused
by S. Choleraesuis. However, in 2002, we isolated for the
first time from a patient with sepsis, a strain of S.
Choleraesuis that was simultaneously resistant to ceftriax-
one and ciprofloxacin (8). The ceftriaxone resistance gene,
blaCMY-2, of this isolate was found on a potentially trans-
missible plasmid (8); thus, the spread of such resistance
phenotype may be unavoidable in the future. In view of the
severe situation, restricted use of antimicrobial agents in
both humans and domestic animals as well as actively
monitoring S. Choleraesuis isolates for antimicrobial drug
resistance should be reinforced.
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